Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia

Table 3 Secondary outcomes, n (%)/mean ± SD/ median (25^th-75^th percentiles)

Outcome	Serum uric acid (mg/dL)	LVEF	NT-proBNP (pg/mL)	QoL score	Cardiovascular death or hospitalization for heart failure
Dapagliflozin group (n = 100)	Baseline: 7.5 ± 1.2; 24 months: 6.3 ± 1.1; Change: -1.2 ± 0.8	Baseline: 32.5 ± 6.7; 24 months: 36.0 ± 6.5; Change: 3.5 ± 2.4	Baseline: 1200 (800-1800); 24 months: 900 (600-1400); Change: -25% (-35% to -15%)	Baseline: 60 (50-70); 24 months: 70 (60-80); Change: 10 (5-15)	18
Placebo group (n = 100)	Baseline: 7.6 ± 1.3; 24 months: 7.5 ± 1.2; Change: -0.1 ± 0.7	Baseline: 33.2 ± 7.1; 24 months: 32.7 ± 7.0; Change: -0.5 ± 2.3	Baseline: 1250 (850-1900); 24 months: 1300 (900-2000); Change: 5% (-10%-20%)	Baseline: 58 (48-68); 24 months: 58 (48-68); Change: 0 (-5-5)	28
P value	< 0.001	< 0.001	< 0.001	< 0.001	0.002; Hazard ratio 95%CI: 0.65 (0.50-0.85)

LVEF: Left ventricular ejection fraction; NT-proBNP: N-terminal pro-B-type natriuretic peptide; QoL: Quality of life.